Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System

Objective: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it's used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). Methods: An observational multicentre retrospective study was conducted. Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the last term of 2011 were included. We collected patients' baseline characteristics, diagnostic and treatment data, effectiveness variables (response to treatment with pemetrexed and overallsurvival) and main adverse reactions detected. Results: 172 patients from 17 hospitals were included (77.33% were men), median age 63 years old (between 34 and 83). The predominant histology was adenocarcinoma (84.30%) and 85.20% were diagnosed of lung cancer with IV-stage. 78.49% had been smokers at some point in their lives. Median overall survival from the start of pemetrexed was 9 months (95%CI, 4.1-13.9). Progression of the disease was the most frequent response (33.14%), only one patient had complete response. Stable disease was associated with a higher probability of survival. Main adverse reactions detected were asthenia, haematological reactions, gastrointestinal reactions and dermal o mucous toxicity. No patients discontinued treatment for serious toxicity. Conclusions: Pemetrexed resulted quite effective in NSCLC when it was used on real clinical practice, with higher survival in non-squamous histology and patients with the best score of Eastern Cooperative Oncology Group scale. The toxicity profile was well tolerated. Prospective studies would be needed to confirm the effect of prognostic factors observed.

Saved in:
Bibliographic Details
Main Authors: Pérez-Moreno,María Antonia, Cotrina-Luque,Jesús, Galván-Banqueri,Mercedes, Flores-Moreno,Sandra, Bautista-Paloma,Francisco Javier, Calleja-Hernández,Miguel Ángel
Format: Digital revista
Language:English
Published: Grupo Aula Médica 2016
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432016000600002
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1130-63432016000600002
record_format ojs
spelling oai:scielo:S1130-634320160006000022017-03-06Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health SystemPérez-Moreno,María AntoniaCotrina-Luque,JesúsGalván-Banqueri,MercedesFlores-Moreno,SandraBautista-Paloma,Francisco JavierCalleja-Hernández,Miguel Ángel Pemetrexed Non-small-cell lung cancer Effectiveness Safety Objective: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it's used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). Methods: An observational multicentre retrospective study was conducted. Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the last term of 2011 were included. We collected patients' baseline characteristics, diagnostic and treatment data, effectiveness variables (response to treatment with pemetrexed and overallsurvival) and main adverse reactions detected. Results: 172 patients from 17 hospitals were included (77.33% were men), median age 63 years old (between 34 and 83). The predominant histology was adenocarcinoma (84.30%) and 85.20% were diagnosed of lung cancer with IV-stage. 78.49% had been smokers at some point in their lives. Median overall survival from the start of pemetrexed was 9 months (95%CI, 4.1-13.9). Progression of the disease was the most frequent response (33.14%), only one patient had complete response. Stable disease was associated with a higher probability of survival. Main adverse reactions detected were asthenia, haematological reactions, gastrointestinal reactions and dermal o mucous toxicity. No patients discontinued treatment for serious toxicity. Conclusions: Pemetrexed resulted quite effective in NSCLC when it was used on real clinical practice, with higher survival in non-squamous histology and patients with the best score of Eastern Cooperative Oncology Group scale. The toxicity profile was well tolerated. Prospective studies would be needed to confirm the effect of prognostic factors observed.Grupo Aula MédicaFarmacia Hospitalaria v.40 n.6 20162016-12-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432016000600002en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Pérez-Moreno,María Antonia
Cotrina-Luque,Jesús
Galván-Banqueri,Mercedes
Flores-Moreno,Sandra
Bautista-Paloma,Francisco Javier
Calleja-Hernández,Miguel Ángel
spellingShingle Pérez-Moreno,María Antonia
Cotrina-Luque,Jesús
Galván-Banqueri,Mercedes
Flores-Moreno,Sandra
Bautista-Paloma,Francisco Javier
Calleja-Hernández,Miguel Ángel
Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System
author_facet Pérez-Moreno,María Antonia
Cotrina-Luque,Jesús
Galván-Banqueri,Mercedes
Flores-Moreno,Sandra
Bautista-Paloma,Francisco Javier
Calleja-Hernández,Miguel Ángel
author_sort Pérez-Moreno,María Antonia
title Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System
title_short Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System
title_full Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System
title_fullStr Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System
title_full_unstemmed Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System
title_sort effectiveness and safety of pemetrexed for non-small cell lung cancer in the andalusian public health system
description Objective: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it's used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). Methods: An observational multicentre retrospective study was conducted. Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the last term of 2011 were included. We collected patients' baseline characteristics, diagnostic and treatment data, effectiveness variables (response to treatment with pemetrexed and overallsurvival) and main adverse reactions detected. Results: 172 patients from 17 hospitals were included (77.33% were men), median age 63 years old (between 34 and 83). The predominant histology was adenocarcinoma (84.30%) and 85.20% were diagnosed of lung cancer with IV-stage. 78.49% had been smokers at some point in their lives. Median overall survival from the start of pemetrexed was 9 months (95%CI, 4.1-13.9). Progression of the disease was the most frequent response (33.14%), only one patient had complete response. Stable disease was associated with a higher probability of survival. Main adverse reactions detected were asthenia, haematological reactions, gastrointestinal reactions and dermal o mucous toxicity. No patients discontinued treatment for serious toxicity. Conclusions: Pemetrexed resulted quite effective in NSCLC when it was used on real clinical practice, with higher survival in non-squamous histology and patients with the best score of Eastern Cooperative Oncology Group scale. The toxicity profile was well tolerated. Prospective studies would be needed to confirm the effect of prognostic factors observed.
publisher Grupo Aula Médica
publishDate 2016
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432016000600002
work_keys_str_mv AT perezmorenomariaantonia effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem
AT cotrinaluquejesus effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem
AT galvanbanquerimercedes effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem
AT floresmorenosandra effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem
AT bautistapalomafranciscojavier effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem
AT callejahernandezmiguelangel effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem
_version_ 1755939077251661824